Show Summary Details
Page of

Supplemental Ultrasound Screening for Women at Increased Breast Cancer Risk: The ACRIN 6666 Trial 

Supplemental Ultrasound Screening for Women at Increased Breast Cancer Risk: The ACRIN 6666 Trial
Chapter:
Supplemental Ultrasound Screening for Women at Increased Breast Cancer Risk: The ACRIN 6666 Trial
Author(s):

Christoph I. Lee

DOI:
10.1093/med/9780190223700.003.0042
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 August 2019

This chapter, found in the cancer screening and management section of the book, provides a succinct synopsis of a key study examining the efficacy of supplemental ultrasound screening for women at increased breast cancer risk. This summary outlines the study methodology and design, major results, limitations and criticisms, related studies and additional information, and clinical implications. The study showed that adding a single screening ultrasound to screening mammography for women at increased risk of breast cancer results in increased detection of cancers, mostly invasive and node-negative. In addition to outlining the most salient features of the study, a clinical vignette and imaging example are included in order to provide relevant clinical context.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.